Healthcare Business Roundup: OraSure Launches HIV Test, Perrigo Wins FDA Okay

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Shares of OraSure Technologies (NASDAQ:OSUR) spiked on word Tuesday that the firm has introduced its OraQuick In-Home HIV test at domestic retailers nationwide and online. The launch represents the first infectious disease test to be ever made available directly to consumers for in-home use. Along with the product intro, the company is also working with a high profile celebrity as part of an ongoing HIV awareness effort.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Perrigo Company (NASDAQ:PRGO) wins an FDA okay to market polacrilex, its over-the-counter mint flavored mini nicotine lozenges, which will be marketed under retailer and wholesalers’store, or own brand labels, and is comparable to GlaxoSmithKline’s (NYSE:GSK) Nicorette Mini Lozenge. The seller says that the lozenge is the first product approved that will be aimed at the individual store brand market.

Roche’s (RHHBY.PK) gantenerumab and Eli Lilly and Company’s (NYSE:LLY) solanezumab and beta secretase inhibitor have been chosen by Washington University in St. Louis for Alzheimer’s prevention trials, that should commence early next year. The trials will be conducted at the university’s Dominantly Inherited Alzheimer’s Network Trials Unit, and should involve 160 people suffering from inherited gene mutations which typically lead to alzheimer’s at a relatively young age.

Don’t Miss: Here’s Why Eli Lilly Can’t Forget Alzheimer’s Treatments.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business